KRASi treatment of PDAC cells with activated ERK1/2
Pa16C PDAC cell lines stably expressing activated ERK (ERK1-R84S/S170D or ERK2-R67S/S153D) subjected to DMSO or MRTX1133/KRAS-G12Ci for 24 hours followed by RNA-sequencing